COMPANY

Organogenesis

HQ: Norwood, MA source · organogenesis.com ↗ · New England

FDA-approved therapeutic company FDA-cleared device company

We manufacture our primary non-placental-based products and use third-party manufacturers for our placental-based products. From public records Source · Feb 26, 2026

Keywords: regenerative medicine

Location: Norwood, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$130.0MRaised (2 yrs)3NIH grants

Timeline

Nov 12, 2024 Raise Private placement — Private placement (Series A preferred): $130M (total, as published), announced Nov 12, 2024. Source: SEC filing. source ↗

Funding

Raised: $130.0M. Last 2 years.

Nov 12, 2024 Private placement — Private placement (Series A preferred): $130M (total, as published), announced Nov 12, 2024. Source: SEC filing. source ↗

NIH awards 3

Annual award amounts. Total $305K.

Aug 21, 2000 NIH award 1R41CA088997-01 FY2000: $154,800 awarded for that fiscal year; activity R41 (STTR); PI SCHWARTZ, PAULINE M; recipient as written: ORGANOGENESIS, INC., CANTON, MA. TISSUE ENGINEERING TO CREATE LIVING EPIDERM source ↗
Sep 28, 1999 NIH award 1R43HL063544-01 FY1999: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI SULLIVAN, SUSAN J; recipient as written: ORGANOGENESIS, INC., CANTON, MA. DEVELOPMENT OF A TISSUE-ENGINEERED VASCULAR G source ↗
Jun 11, 1991 NIH award 1R43EY009014-01 FY1991: $49,710 awarded for that fiscal year; activity R43 (SBIR); PI PARENTAEAU, NANCY L; recipient as written: ORGANOGENESIS, INC., CANTON, MA. CONSTRUCTION OF A HUMAN CORNEA IN VITRO source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2024-11-27 Raise Private raise (SEC Form D): $130.0M sold; issuer “Organogenesis Holdings Inc.”. Verified from the SEC filing. SEC filing ↗